{"Symbol": "ACIU", "AssetType": "Common Stock", "Name": "AC Immune Ltd", "Description": "AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company is headquartered in Lausanne, Switzerland.", "CIK": "1651625", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "BUILDING B, LAUSANNE, SWITZERLAND, 1015", "OfficialSite": "https://www.acimmune.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "300794000", "EBITDA": "-71652000", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.805", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-0.94", "RevenuePerShareTTM": "0.044", "ProfitMargin": "0", "OperatingMarginTTM": "-16.72", "ReturnOnAssetsTTM": "-0.22", "ReturnOnEquityTTM": "-0.746", "RevenueTTM": "4372000", "GrossProfitTTM": "-57226000", "DilutedEPSTTM": "-0.94", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "-0.963", "AnalystTargetPrice": "9.21", "AnalystRatingStrongBuy": "0", "AnalystRatingBuy": "4", "AnalystRatingHold": "0", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "0", "TrailingPE": "-", "ForwardPE": "11.24", "PriceToSalesRatioTTM": "68.8", "PriceToBookRatio": "3.715", "EVToRevenue": "29.21", "EVToEBITDA": "-0.764", "Beta": "1.625", "52WeekHigh": "4", "52WeekLow": "1.43", "50DayMovingAverage": "3.23", "200DayMovingAverage": "2.615", "SharesOutstanding": "100600000", "SharesFloat": "40064900", "PercentInsiders": "38.006", "PercentInstitutions": "25.194", "DividendDate": "None", "ExDividendDate": "None"}